|Table of Contents|

Analysis of prognostic factors and construction of a nomogram for lenvatinib treatment in unresectable hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
73-80
Research Field:
Publishing date:

Info

Title:
Analysis of prognostic factors and construction of a nomogram for lenvatinib treatment in unresectable hepatocellular carcinoma
Author(s):
LU Huirong; DENG Lian; LU Meijun; LIU Shaobing; CHEN Xi
Nanxishan Hospital of Guangxi Zhuang Autonomous Region,Guangxi Guilin 541001,China.
Keywords:
hepatocellular carcinoma; lenvatinib; prognostic model; nomogram
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2025.01.012
Abstract:
Objective:To develop and validate a nomogram model for predicting the survival outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with lenvatinib.Methods:We retrospectively included 170 uHCC patients treated with lenvatinib (training cohort:n=118，validation cohort:n=52).Univariate Cox regression was used to screen for potential factors affecting OS,and multivariate Cox analysis was used to assess independent prognostic factors and construct the nomogram model.The model's performance and predictive accuracy were evaluated using the concordance index (C-index),calibration curves,and decision curve analysis (DCA).Results:The final model was built using six factors that affect prognosis.The C-index of the nomogram in the training cohort and validation cohort was 0.763 and 0.784 respectively.Calibration curve showed good agreement between predicted probabilities and actual outcomes.Based on the nomogram scores,the mOS for low and high-risk groups was 15.5 and 12.1 months,respectively (P=0.000).Conclusion:The nomogram model in this study demonstrated favorable predictive performance,capable of accurately predicting the survival outcomes of uHCC patients receiving lenvatinib treatment.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ LLOVET JM,KELLEY RK,VILLANUEVA A,et al.Hepatocellular carcinoma［J］.Nature Reviews Disease Primers,2021,7(1):6.
［3］ IKEDA K,KUDO M,KAWAZOE S,et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma［J］.Journal of Gastroenterology,2017,52(4):512-519.
［4］ KUDO M,FINN RS,QIN S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial［J］.Lancet,2018,391(10126):1163-1173.
［5］ WANG Q,XIA D,BAI W,et al.Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma:a multicentre observational study［J］.Journal of Hepatology,2019,70(5):893-903.
［6］ ANAND S,POTTAKKAT B,RAJA K,et al.Transarterial chemoembolization in patients with hepatocellular carcinoma beyond Barcelona-Clinic Liver Cancer-B and portal vein tumor thrombosis:Experience from a tertiary care center［J］.Indian Journal of Cancer,2022,59(3):325-329.
［7］ PATIDAR Y,CHANDEL K,CONDATI NK,et al.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE in patients with BCLC stage C hepatocellular carcinoma-a retrospective study［J］.J Clin Exp Hepatol,2022,12(3):745-754.
［8］ PATIDAR Y,MUKUND A,SARIN SK.Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a tertiary care center experience［J］.Indian J Radiol Imaging,2021,31(2):270-276.
［9］ KUDO M.Proposal of primary endpoints for TACE combination trials with systemic therapy:lessons learned from 5 negative trials and the positive tactics trial［J］.Liver Cancer,2018,7(3):225-234.
［10］ WANG B,XU H,GAO ZQ,et al.Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization［J］.Acta Radiologica,2008,49(5):523-529.
［11］ PAWLIK TM,REYES DK,COSGROVE D,et al.Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma［J］.Journal of Clinical Oncology,2011,29(30):3960-3967.
［12］ HATO T,ZHU AX,DUDA DG.Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma［J］.Immunotherapy,2016,8(3):299-313.
［13］ WANG Y,JIANG M,ZHU J,et al.The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma［J］.Biomedicine & Pharmacotherapy,2020,132:110797.
［14］ FINN RS,IKEDA M,ZHU AX,et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］.Journal of Clinical Oncology,2020,38(26):2960-2970.
［15］ CAI M,HUANG W,HUANG J,et al.Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma:a retrospective cohort study［J］.Frontiers in Immunology,2022,13:848387.
［16］ RAPPOSELLI IG,SHIMOSE S,KUMADA T,et al.Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma［J］.ESMO Open,2021,6(4):100190.
［17］ CAO W,CHEN HD,YU YW,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020［J］.Chin Med J (Engl),2021,134(7):783-791.
［18］ IASONOS A,SCHRAG D,RAJ GV,et al.How to build and interpret a nomogram for cancer prognosis［J］.Journal of Clinical Oncology,2008,26(8):1364-1370.
［19］ BALACHANDRAN VP,GONEN M,SMITH JJ,et al.Nomograms in oncology:more than meets the eye［J］.The Lancet Oncology,2015,16(4):e173-e180.
［20］ KANG X,LIU X,LI Y,et al.Development and evaluation of nomograms and risk stratification systems to predict the overall survival and cancer-specific survival of patients with hepatocellular carcinoma［J］.Clinical and Experimental Medicine,2024,24(1):44.
［21］ KUO HY,CHIANG NJ,CHUANG CH,et al.Impact of immune checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on organ-specific efficacy and macrovascular invasion in advanced hepatocellular carcinoma［J］.Oncology Research and Treatment,2020,43(5):211-220.
［22］ TSUCHIYA K,KUROSAKI M,SAKAMOTO A,et al.The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study［J］.Cancers (Basel),2021,13(11):2608.
［23］ WU CJ,LEE PC,HUNG YW,et al.Lenvatinib plus pembrolizumab for systemic therapy-naive and -experienced unresectable hepatocellular carcinoma［J］.Cancer Immunol Immunother,2022,71(11):2631-2643.
［24］ LEE J,SUNG PS,YANG H,et al.A real-world comparative analysis of lenvatinib and sorafenib as a salvage therapy for transarterial treatments in unresectable HCC［J］.Journal of Clinical Medicine,2020,9(12):4121.
［25］ SHIMOSE S,KAWAGUCHI T,TANAKA M,et al.Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization:a multicenter cohort study using data mining analysis［J］.Oncology Letters,2020,20(3):2257-2265.
［26］ CHENG AL,HSU C,CHAN SL,et al.Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma［J］.Journal of Hepatology,2020,72(2):307-319.
［27］ GORDAN JD,KENNEDY EB,ABOU-ALFA GK,et al.Systemic therapy for advanced hepatocellular carcinoma:ASCO guideline［J］.Journal of Clinical Oncology,2020,38(36):4317-4345.
［28］ HUTCHINSON L.Targeted therapies:Lenvatinib selects survival benefit［J］.Nature Reviews Endocrinology,2017,13(9):500.
［29］ FINN RS,QIN S,IKEDA M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］.New England Journal of Medicine,2020,382(20):1894-1905.
［30］ LLOVET JM,KUDO M,MERLE P,et al.Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002):a randomised,double-blind,phase 3 trial［J］.Lancet Oncology,2023,24(12):1399-1410.
［31］ CHENG S,YANG J,SHEN F,et al.Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus-Eastern hepatobiliary surgical hospital consensus statement［J］.Oncotarget,2016,7(26):40816-40829.
［32］ HUANG J,CAI M,HUANG W,et al.Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus:a retrospective controlled study［J］.Chin Med J (Engl),2022,135(1):113-115.
［33］ JIANG JF,LAO YC,YUAN BH,et al.Treatment of hepatocellular carcinoma with portal vein tumor thrombus:advances and challenges［J］.Oncotarget,2017,8(20):33911-33921.
［34］ CHAN AW,KUMADA T,TOYODA H,et al.Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma［J］.J Gastroenterol Hepatol,2016,31(7):1300-1306.
［35］ FENG D,WANG M,HU J,et al.Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases［J］.Annals of Translational Medicine,2020,8(8):553.
［36］ ELSHAARAWY O,ALKHATIB A,ELHELBAWY M,et al.Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma［J］.World J Hepatol,2019,11(6):542-552.

Memo

Memo:
广西桂林市自筹经费科技项目（编号：20220122z）
Last Update: 1900-01-01